HYDRA试验:大分割剂量重分布放疗对比常规放疗治疗头颈癌的期中分析
HYDRA I期试验旨在通过大分割和剂量重分布减少口咽及下咽鳞癌(放)化疗的治疗负担和放射性淋巴细胞减少。光子队列10例期中分析显示1例剂量限制性毒性(放射性骨坏死),中位随访10.6个月无其他晚期≥3级毒性。20次HYDRA方案对肿瘤GTV给予局灶加量,同时降低所有危及器官剂量。
要点
- HYDRA光子队列期中分析(n=10)仅1例剂量限制性毒性,无其他晚期≥3级毒性。
- 20次HYDRA方案: elective体积40 Gy,GTV+5mm 55 Gy,GTV-3mm 59 Gy。
- 计划比较显示HYDRA对GTV平均剂量59.6 Gy,危及器官剂量降低。
核心结论
- HYDRA光子队列预设期中分析显示1例剂量限制性毒性,按方案可扩展至喉癌入组。
- 20次HYDRA方案实现肿瘤局灶加量并降低所有危及器官剂量。
研究设计与样本
- HYDRA为I期试验(NCT05364411),入组cT1-4 N0-3bM0口咽和下咽癌接受根治性(放)化疗的患者。
- 根据荷兰方案模型选择分为HYDRA质子队列和HYDRA光子队列。
- 每队列10例完成6个月随访时进行安全性期中分析,预设剂量限制性毒性决定试验继续和扩展。
主要发现
- HYDRA光子队列期中分析于2024年3月达到n=10,出现1例剂量限制性毒性(放射性骨坏死)。
- 中位随访10.6个月,无其他晚期≥3级毒性。
- 全部入组HYDRA患者(光子n=14,质子n=5)的个体内计划比较显示,HYDRA对GTV的Dmean为59.6 Gy(范围59.0-60.1 Gy)。
- 危及器官平均剂量降低:HYDRA光子0.4-4.5 Gy EQD2,HYDRA质子2.1-5.0 GyE EQD2。
关键数值与推荐
- HYDRA分20次: elective体积40 Gy,GTV+5mm 55 Gy,GTV-3mm 59 Gy。
- HYDRA光子队列期中分析n=10,1例剂量限制性毒性(放射性骨坏死),中位随访10.6个月无其他晚期≥3级毒性。
- HYDRA对GTV的Dmean 59.6 Gy(范围59.0-60.1 Gy)。
- 危及器官剂量降低:HYDRA光子0.4-4.5 Gy EQD2,HYDRA质子2.1-5.0 GyE EQD2。
临床怎么用
- HYDRA光子队列期中分析结果支持按方案将喉癌纳入光子队列。
- 20次HYDRA方案可在给予肿瘤局灶加量的同时降低危及器官剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: (Chemo)radiotherapy for squamous cell carcinoma of the oropharynx, hypopharynx, and larynx results in significant treatment burden and may cause radiation-induced lymphopenia (RIL), which is associated with worse survival. We aim to reduce treatment burden and RIL using HYpofractionation and Dose-redistribution in patients treated with proton or photon RAdiotherapy (HYDRA, NCT05364411). METHODS: Patients receiving curative (chemo)radiotherapy for cT1-4 N0-3bM0 oropharyngeal and hypopharyngeal carcinomas are eligible. Referral for proton therapy is determined by model-based selection (MBS) according to Dutch protocols, resulting in a HYDRA-proton and HYDRA-photon cohort. HYDRA in 20 fractions constitutes 40 Gy to the elective volume, 55 Gy to gross tumour volume (GTV) + 5 mm and 59 Gy to GTV - 3 mm. Safety interim analyses are conducted in each cohort when ten patients complete 6 months follow-up. The interim results determine trial continuation and expansion to inclusion of laryngeal carcinomas according to predefined dose limiting toxicities (DLT). Per included HYDRA-patient, we perform an intra-patient plan comparison of the HYDRA plan versus the conventional treatment plan that was used for MBS. RESULTS: The HYDRA-photon interim analysis (reached in March 2024, n = 10) showed one DLT (osteoradionecrosis), with no other late grade ≥ 3 toxicity after a median follow-up of 10.6 months. Among all enrolled HYDRA-patients (photons: n = 14; protons: n = 5), intra-patient plan comparison showed that HYDRA delivered a focal boost of Dmean 59.6 Gy (range 59.0-60.1 Gy) to the GTV, while on average, organs at risk received a reduced dose (HYDRA-photons: 0.4-4.5 Gy EQD2; HYDRA-protons: 2.1-5.0 GyE EQD2). CONCLUSIONS: The predefined interim analysis of HYDRA-photons showed one DLT. Per protocol, inclusion of laryngeal carcinomas in the photon cohort is now possible. The 20 fraction HYDRA schedule delivers a focal boost to the tumour with reduced dose to all organs at risk.
引用
- Gunsch PA, Kroesen M, Debets R, et al. HYpofractionated, dose-redistributed RAdiotherapy (HYDRA) versus conventional radiotherapy for head and neck cancer: planned interim analysis and dosimetric comparison from the phase I HYDRA trial. Clin Transl Radiat Oncol. 2026. PMID: 41685200. doi:10.1016/j.ctro.2026.101113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。